Sage Therapeutics (SAGE) and Its Competitors Financial Review
Sage Therapeutics (NASDAQ: SAGE) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Sage Therapeutics to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk.
Institutional & Insider Ownership
46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.1% of Sage Therapeutics shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Sage Therapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Sage Therapeutics||N/A||-$222.35 million||-10.26|
|Sage Therapeutics Competitors||$207.83 million||-$2.34 million||0.17|
Sage Therapeutics’ peers have higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Sage Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sage Therapeutics Competitors||-3,989.23%||-119.42%||-44.20%|
Volatility and Risk
Sage Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500. Comparatively, Sage Therapeutics’ peers have a beta of 1.63, indicating that their average share price is 63% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Sage Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sage Therapeutics Competitors||469||2235||6130||118||2.66|
Sage Therapeutics currently has a consensus target price of $86.79, suggesting a potential upside of 39.84%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 0.21%. Given Sage Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Sage Therapeutics is more favorable than its peers.
Sage Therapeutics beats its peers on 7 of the 12 factors compared.
About Sage Therapeutics
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.